Nephrotic Syndrome - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Nephrotic Syndrome - Pipeline Review, H1 2016', provides an overview of the Nephrotic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome - The report reviews pipeline therapeutics for Nephrotic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Nephrotic Syndrome therapeutics and enlists all their major and minor projects - The report assesses Nephrotic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Nephrotic Syndrome Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Nephrotic Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nephrotic Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Nephrotic Syndrome Overview 6 Therapeutics Development 7 Pipeline Products for Nephrotic Syndrome - Overview 7 Pipeline Products for Nephrotic Syndrome - Comparative Analysis 8 Nephrotic Syndrome - Therapeutics under Development by Companies 9 Nephrotic Syndrome - Therapeutics under Investigation by Universities/Institutes 10 Nephrotic Syndrome - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Nephrotic Syndrome - Products under Development by Companies 14 Nephrotic Syndrome - Products under Investigation by Universities/Institutes 15 Nephrotic Syndrome - Companies Involved in Therapeutics Development 16 Asahi Kasei Pharma Corp. 16 Bristol-Myers Squibb Company 17 Orbis Biosciences, Inc. 18 Retrophin Inc. 19 Nephrotic Syndrome - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 abatacept - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 cosyntropin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 mizoribine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 prednisone - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Recombinant Proteins to Inhibit Complement C3 for Nephrosis - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SP-20104 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Nephrotic Syndrome - Recent Pipeline Updates 38 Nephrotic Syndrome - Dormant Projects 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for Nephrotic Syndrome, H1 2016 7 Number of Products under Development for Nephrotic Syndrome - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp., H1 2016 16 Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2016 17 Nephrotic Syndrome - Pipeline by Orbis Biosciences, Inc., H1 2016 18 Nephrotic Syndrome - Pipeline by Retrophin Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Nephrotic Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 38 Nephrotic Syndrome - Dormant Projects, H1 2016 42
List of Figures
Number of Products under Development for Nephrotic Syndrome, H1 2016 7 Number of Products under Development for Nephrotic Syndrome - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Top 10 Targets, H1 2016 21 Number of Products by Stage and Top 10 Targets, H1 2016 21 Number of Products by Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and productRead More...
Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceuticaRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.